Results 161 to 170 of about 1,396 (170)

Validation of a Therapeutic Range for Nitisinone in Patients Treated for Tyrosinemia Type 1 Based on Reduction of Succinylacetone Excretion

JIMD Reports, 2019
C Ronald Scott
exaly  

LC-MS/MS Study of the Degradation Processes of Nitisinone and Its By-Products

Journal of Pharmaceutical and Biomedical Analysis, 2019
Rafał Rola, Hanna Barchańska, Wojciech Szczepankiewicz   +2 more
exaly  

Nitisinone use in hereditary tyrosinemia and alkaptonuria

2010
Wendy J. Introne, Kevin J. O'Brien, William A. Gahl   +2 more
openaire   +1 more source

LIQUID PHARMACEUTICAL COMPOSITION COMPRISING NITISINONE

2012
SVENSSON LENNART, SIDEN HANS
openaire   +5 more sources

Nitisinon experience in alkaptonuria patients

2019
ARSLAN, SEZAİ, Kadıoğlu Yılmaz, banu, KARDAŞ, FATİH, KENDİRCİ, MUSTAFA, Alakuş Sarı, Ümmü   +4 more
openaire   +1 more source

Nitisinone for the treatment of alkaptonuria: FDA approval summary

Molecular Genetics and Metabolism
Daniela Varela Luquetti, Emily Morris
openaire   +1 more source

Human medicines European public assessment report (EPAR): Nitisinone MDK (previously Nitisinone MendeliKABS), nitisinone, Tyrosinemias, Date of authorisation: 24/08/2017, Revision: 2, Status: Authorised

Case Medical Research, 2019
openaire   +1 more source

In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.

The Medical letter on drugs and therapeutics, 2017
openaire   +1 more source

NITISINONE DOSING REGIMENS FOR THE TREATMENT OF ALKAPTONURIA

2015
openaire   +1 more source

NITISINONE FOR TREATMENT OF OCULOCUTANEOUS/OCULAR ALBINISM AND FOR INCREASING PIGMENTATION

2011
BROOKS BRIAN P, GAHL WILLIAM A
openaire   +6 more sources